Adding cost to NNT: the COPE statistic

Maharaj, Rohan
January 2008
ACP Journal Club;Jan/Feb2008, Vol. 148 Issue 1, pA8
Academic Journal
The author reflects on the capacity of cost-effectiveness analysis for clinicians and policymakers, Cost of Preventing an Event (COPE), to evaluate their economic actions and consequences in the U.S. He asserts that the cost analysis is an incomplete form of economic appraisal for it ignores the two elements including cost offsets and adverse effects of treatment. He suggests that the individual medical practitioners need to justify the cost of therapy based on the prevalence of a disease.


Related Articles

  • Closing The Doughnut Hole: No Easy Answers. Danzon, Patricia M. // Health Affairs;Jul-Dec2004 Supplement 2, Vol. 23, p405 

    The price differentials reported by Gerard Anderson and colleagues are not fully representative and are probably biased upward. If Congress does seek to reduce drug prices, there are no simple, effective, and efficient strategies. The most likely is drug importation, which would be ineffective...

  • Cost-Related Nonadherence to Medications Among Patients With Diabetes and Chronic Pain. Kurlander, Jacob E.; Kerr, Eve A.; Krein, Sarah; Heisler, Michele; Piette, John D. // Diabetes Care;Dec2009, Vol. 32 Issue 12, p2143 

    OBJECTIVE -- In the face of financial constraints, diabetic patients may forgo prescribed medications, causing negative health effects. This study examined how cost and noncost factors are associated with patterns of cost-related nonadherence to medications (CRN). RESEARCH DESIGN AND METHODS --...

  • Analysis suggests zanamivir first choice for 'flu in Japan.  // PharmacoEconomics & Outcomes News;1/29/2005, Issue 470, p7 

    Presents the results of a study on the cost effectiveness of several treatment options for influenza or influenza-like illnesses in Tokyo, Japan. Use of a decision-analysis model to estimate the cost effectiveness of oseltamivir, zanamivir and a control agent; Comparison of the time to...

  • Temozolomide more cost effective than combo therapy in glioblastoma.  // PharmacoEconomics & Outcomes News;8/27/2005, Issue 485, p5 

    Discusses research being done on cost efficiency of using temozolomide in the treatment of recurrent glioblastoma multiforme. Reference to a study by J. A. Martikainen and colleagues, published in a 2005 issue of the journal "PharmacoEconomics"; Method used to analyze the cost effectiveness of...

  • Evaluación de un modelo de predicción del gasto farmacéutico en atención primaria de salud basado en variables demográficas. Santamargarita-Pérez, Sonia; Sancho-Mestre, Carla; Vivas-Consuelo, David; Usó-Talamantes, Ruth // Revista Gerencia y Políticas de Salud;jul-dic2013, Vol. 12 Issue 25, p56 

    Problem: In the current context of budget constraints in the health sector management systems that allow allocating spending more efficiently are required. In the case of pharmaceutical expenditure, risk adjustment models are tools that help to improve the efficiency. Objectives: To evaluate the...

  • Improving cost-effectiveness in the health-care sector.  // OECD Economic Surveys: Iceland;Feb2008, Vol. 2008 Issue 3, p75 

    Health outcomes and the quality of health care are very good by international comparison, while income-related health inequality appears to be smaller than in most other countries. However, the health-care system is costly and, according to OECD estimates, public expenditure on health and...

  • Why do drugs $ cost so much? Gibbs, Lisa // Money;Fall2003, Vol. 32 Issue 11, p94 

    Answers questions about the cost of prescription drugs in the United States. Discussion of why drugs cost so much and why they are cheaper overseas; The reason for the fast growth in drug spending and why people are taking so many pills; Effect of marketing on drug spending; Benefits of an...

  • Health-Economic Comparison of Paricalcitol, Calcitriol and Alfacalcidol for the Treatment of Secondary Hyperparathyroidism during Haemodialysis. Rosery, Hubertus; Bergemann, Rito; Marx, Steven E.; Boehnke, Axel; Melnick, Joel; Sterz, Raimund; Williams, Laura // Clinical Drug Investigation;2006, Vol. 26 Issue 11, p629 

    This study evaluated the health-economic consequences of use of intravenous paricalcitol (Zemplar), oral calcitriol or oral and intravenous alfacalcidol for the treatment of patients with secondary hyperparathyroidism, focusing on a third-party payer perspective through inclusion of medication...

  • Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions. Sinha, Gunjan // JNCI: Journal of the National Cancer Institute;10/1/2008, Vol. 100 Issue 19, p1347 

    The article focuses on highly priced cancer drugs with low benefits in the U.S. Justification on high prices charged on drugs medication with unproven benefits has been the issue in the healthcare sector. These caused a long debate on how American patients can use the health care system under a...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics